173 related articles for article (PubMed ID: 33902692)
1. Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
Okita Y; Kano-Fujiwara R; Nakatsuka SI; Honma K; Kinoshita M
Exp Hematol Oncol; 2021 Apr; 10(1):29. PubMed ID: 33902692
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
[TBL] [Abstract][Full Text] [Related]
3. Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Yonezawa H; Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Aoi A; Nishikawa R
Neurooncol Adv; 2024; 6(1):vdae037. PubMed ID: 38690230
[TBL] [Abstract][Full Text] [Related]
4. Tirabrutinib: First Approval.
Dhillon S
Drugs; 2020 Jun; 80(8):835-840. PubMed ID: 32382949
[TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
Schaff L; Nayak L; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38597202
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
[TBL] [Abstract][Full Text] [Related]
7. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
8. Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment.
Yoshioka H; Okuda T; Nakao T; Fujita M; Takahashi JC
Anticancer Res; 2022 Aug; 42(8):4173-4178. PubMed ID: 35896257
[TBL] [Abstract][Full Text] [Related]
9. Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.
Arakawa Y; Narita Y; Nagane M; Mishima K; Terui Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Aoi A; Nishikawa R
Neurooncol Adv; 2023; 5(1):vdad109. PubMed ID: 37744697
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Munakata W; Ando K; Hatake K; Fukuhara N; Kinoshita T; Fukuhara S; Shirasugi Y; Yokoyama M; Ichikawa S; Ohmachi K; Gion N; Aoi A; Tobinai K
Cancer Sci; 2019 May; 110(5):1686-1694. PubMed ID: 30815927
[TBL] [Abstract][Full Text] [Related]
11. Tirabrutinib hydrochloride for B-cell lymphomas.
Munakata W; Tobinai K
Drugs Today (Barc); 2021 Apr; 57(4):277-289. PubMed ID: 33851691
[TBL] [Abstract][Full Text] [Related]
12. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
Guo HP; Dang XL; Kang L; Liu C; Liu XW
World Neurosurg; 2024 Apr; 188():161-169. PubMed ID: 38641241
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Shiibashi R; Izutsu K
Cancer Sci; 2020 Sep; 111(9):3327-3337. PubMed ID: 32639651
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.
Munakata W; Ando K; Yokoyama M; Fukuhara N; Yamamoto K; Fukuhara S; Ohmachi K; Mishima Y; Ichikawa S; Ogiya D; Aoi A; Hatsumichi M; Tobinai K
Int J Hematol; 2023 Apr; 117(4):553-562. PubMed ID: 36576659
[TBL] [Abstract][Full Text] [Related]
15. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
16. Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
Kozaki R; Vogler M; Walter HS; Jayne S; Dinsdale D; Siebert R; Dyer MJS; Yoshizawa T
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29690649
[TBL] [Abstract][Full Text] [Related]
17. The Pharmacokinetic Interaction of Tirabrutinib with Voriconazole, Itraconazole, and Fluconazole in SD Rats by UPLC-MS/MS.
Xia M; Liu YN; Chen J; Xu RA; Dai G
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38213178
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics.
Kozaki R; Yasuhiro T; Kato H; Murai J; Hotta S; Ariza Y; Sakai S; Fujikawa R; Yoshida T
PLoS One; 2023; 18(3):e0282166. PubMed ID: 36897912
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
Yamagami J; Ujiie H; Aoyama Y; Ishii N; Tateishi C; Ishiko A; Ichijima T; Hagihara S; Hashimoto K; Amagai M
J Dermatol Sci; 2021 Sep; 103(3):135-142. PubMed ID: 34376340
[TBL] [Abstract][Full Text] [Related]
20. Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption.
Ariza Y; Murata M; Ueda Y; Yoshizawa T
Bone Rep; 2019 Jun; 10():100201. PubMed ID: 30956999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
